1. Home
  2. NSPR vs IMMP Comparison

NSPR vs IMMP Comparison

Compare NSPR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

SELL

Current Price

$0.60

Market Cap

38.9M

Sector

Health Care

ML Signal

SELL

Logo Immutep Limited

IMMP

Immutep Limited

SELL

Current Price

$3.48

Market Cap

31.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NSPR
IMMP
Founded
2005
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
31.5M
IPO Year
2009
2012

Fundamental Metrics

Financial Performance
Metric
NSPR
IMMP
Price
$0.60
$3.48
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $3.33
N/A
AVG Volume (30 Days)
★ 404.0K
26.0K
Earning Date
11-12-2026
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $2,310,000.00
N/A
Revenue This Year
$9.14
N/A
Revenue Next Year
$105.44
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.43
$0.26
52 Week High
$2.17
$5.36

Technical Indicators

Market Signals
Indicator
NSPR
IMMP
Relative Strength Index (RSI) 49.18 52.67
Support Level $0.43 $3.06
Resistance Level $0.77 $3.55
Average True Range (ATR) 0.11 0.33
MACD 0.01 -0.02
Stochastic Oscillator 44.74 49.61

Price Performance

Historical Comparison
NSPR
IMMP

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: